Symptomatic COVID-19 Infection Laboratory-Confirmed Clinical Trial
Official title:
Evaluation of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
Plasma from patients who have recovered from coronavirus disease 2019 (COVID-19) is referred to as COVID-19 convalescent plasma (CCP), and may contain antibodies against SARS-CoV-2, the virus responsible for COVID-19. CCP infusion is being evaluated as a therapeutic or prophylactic approach in COVID-19 patients. The goal of this study is to help develop a bank of convalescent plasma in California, especially in medically underserved communities particularly affected by the disease. In parallel, CCP administered to COVID-19 patients will be collected and analyzed to determine whether the antibody profile correlates with clinical outcome. The purpose of this non-therapeutic study is to learn more about the CCP antibody profile and the effect it may have in treating COVID-19 infection.
PRIMARY OBJECTIVES: I. Establish a testing service for screening prospective donors of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP). II. Characterize the titer and neutralizing properties of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in CCP. III. Correlate the SARS-CoV-2 antibody characteristics in CCP with the outcome in severely ill COVID-19 patients treated with CCP. EXPLORATORY OBJECTIVES: I. Facilitate the recruitment of CCP donors in medically underserved areas. II. Develop high-throughput methods for detection/characterization of SARS-CoV-2 neutralizing and non-neutralizing antibodies. III. Develop a bank of convalescent plasma that would be available for future studies relating to the content of CCP. IV. Study the impact of antibody levels, donor characteristics and patient characteristics on outcome in COVID-19 patients treated with CCP. V. Procure blood samples from COVID-19 convalescent volunteers for future COVID-19-related studies. OUTLINE: PROSPECTIVE CCP DONORS: Participants undergo collection of blood and/or nasopharyngeal swabs at the time of screening. Participants' medical records are reviewed. CONVALESCENT BLOOD DONORS WHO CHOOSE NOT TO DONATE CCP: Participants undergo collection of blood sample at the time of screening. Participants' medical records are reviewed. CCP RECIPIENTS: Patients undergo collection collection of blood samples at baseline, between CCP unit infusions, 24 hours after last CCP infusion, and between 14-28 after last CCP infusion. Patients' medical records are reviewed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06063330 -
Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects
|
Phase 1 | |
| Completed |
NCT04439006 -
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
|
Phase 1 | |
| Withdrawn |
NCT04665115 -
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
|
Phase 2 | |
| Suspended |
NCT04379518 -
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT04370834 -
Tocilizumab for Patients With Cancer and COVID-19 Disease
|
Phase 2 | |
| Withdrawn |
NCT04455958 -
Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year
|
Phase 2 | |
| Terminated |
NCT04373044 -
Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
|
Phase 2 | |
| Active, not recruiting |
NCT04433949 -
Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19
|
Phase 3 | |
| Recruiting |
NCT04565665 -
Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome
|
Phase 1/Phase 2 | |
| Terminated |
NCT04532372 -
Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05101213 -
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
|
Phase 1 | |
| Active, not recruiting |
NCT04742595 -
Viral Specific T Cell Therapy for COVID-19 Related Pneumonia
|
Early Phase 1 | |
| Withdrawn |
NCT04830735 -
Dasatinib for the Treatment of Moderate and Severe COVID-19
|
Phase 2 |